You just read:

Oncopeptides Completes Enrollment to the Pivotal Phase 3 Study OCEAN for Relapsed Refractory Multiple Myeloma - 450 Patients Included

News provided by

Oncopeptides AB

May 22, 2020, 02:18 ET